Rex Eupseiphos, I normally run the same statistical

New Post Public Reply Private Reply Replies (1) Message Board
TechGuru Rex Eupseiphos #35161
939
Rex Eupseiphos,

I normally run the same statistical analysis that FDA will do with the data to try and make an idea of where I stand with my investment (and re-allocate accordingly).

At the end of the day, we can talk all day long, but if we do not demonstrate significance (p<0.05) we are toasted and FDA will not approve .

So, in the case of Severe or Critical, the primary end point is survival:

Quote:
Primary Outcome Measures :
All-cause mortality at Day 28


The Montefiore patients where perhaps beyond critical (worse) but, lets assume they where in the trial "normal" population. We know that there have been reported deaths of 88% for this cohort.

https://pubmed.ncbi.nlm.nih.gov/32320003/


The question is: How many need to survive for statistical significance ?? Using a two-tailed test and binomial distribution we obtain that 4 patients survival will yield a p-number of p=0.0239 5 patients 0.00371 and 6 patients 0.000406

So, I will say we obtained statistical significance with the Montefiore patients as per Dr. Patterson paper (if more than 4 are alive at day 28)

Now, if we take the Southern California cohort the (31/32) number is even better (to put it mildly), however not sure if all of them where in the Severe or Critical condition, so I prefer not to run any numbers with this cohort, but, let me just say, if they where mild to moderate, we would crush the p-number (to use NP words) just the same as if they where Severe to Critical.

Any way you slice it we are good. Let's hope the trial shows the same response as the results reported so far.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

NAMSA, AMS Partner to Fast-Track Tissue-Healing Tech

Updated Category News Views 97

Streamlining the Path to Market I tell you, the medical device sector is no walk in the park these days. Between the regulators breathing down your neck and the endless red tape, getting a new product from the lab to the hospital floor can feel like running a marathon in quicksand. That's why this deal between NAMSA and Advanced Medical Solutions (AMS) has me taking a...

Continue Reading
VILVA's Global Reach: Power Testing's Next Phase

Updated Category News Views 23

A Power Play on Global Markets Taking a page from its relentless pursuit of quality and innovation, VILVA Electronics is bolstering its foothold on the international stage. Based in Shenzhen, this savvy player is reaching out for strategic partners like fishing for that perfect bite, hoping to reel in catches that understand the nitty-gritty of the local ponds—their...

Continue Reading
AI Faces Accountability Trials in Business 2027

Updated Category News Views 105

Charting the AI Accountability Course In 2027, the corporate AI landscape won't be the Wild West anymore; it's morphing into a structured battlefield where the winners will be those who successfully enforce accountability. The hands-off, carte blanche days of AI are fading fast, and businesses are starting to scrutinize the AI tools they've been throwing money at. "The...

Continue Reading
Global Vineyards List: New Entrants & Rankings Unveiled

Updated Category News Views 212

Vineyards' Global Ranking Unveiled Wine enthusiasts and globetrotters have something to toast about this November. The 50 Best Vineyards just expanded its ranking to reveal the vineyards sitting in spots 51 through 100 for 2026. This list, spotlighting some of the globe's finest wine destinations, precedes the main awards ceremony set for November 18 in Santiago, Chile....

Continue Reading
Net at Work Enhances Offering with K&R Acquisition

Updated Category News Views 24

Net at Work Makes a Strategic Move Out of the blue, Net at Work, a prominent figure in the North American tech scene, zeroes in on boosting their expertise with the acquisition of K&R Consulting Group. It's all about expanding their horizons, and snagging K&R doesn't just double down on their ERP game, it broadens their client base in manufacturing, distribution, and...

Continue Reading
Goodyear's Strategic Shift: New Leadership, New Path

Updated Category News Views 100

Big Shoes, Bigger Expectations Who's steering the Goodyear ship now that Mark Stewart's out the door? Roger Wood's the name, interim CEO is the game. Don't fret too much—the board's hustling to nail down a permanent top dog. But this isn't a musical chairs game; it's a full-on strategic shift. Goodyear's forming committees, juggling ideas, and ripping through their...

Continue Reading
Zions Bank Spurs Idaho's Small Biz Boom in 2026

Updated Category News Views 85

Riding the Small Business Tsunami in Idaho You don't hear it every day, but Idaho's small business scene is hotter than a frypan—a nod to the entrepreneurial fire blazing in the state, and Zions Bank is holding the torch. In 2026, despite dealing with the uphill battles of inflation, tariffs, and labor scarcity, those entrepreneurs still managed to carve out a spot at...

Continue Reading
California Credit Union's Toy Drive Brings Holiday Cheer

Updated Category News Views 44

California Credit Union Joins Forces for Holiday Toy Drive Alright, folks, here’s a story with a feel-good spin straight out of Glendale. California Credit Union is at it again, teaming up with the Los Angeles Boys & Girls Club to sprinkle some holiday magic on local kiddos and their families. Now, it’s the sixth year straight they’ve pulled off this toy drive...

Continue Reading
Veterinary Stories Transform Pet Care in New Docuseries

Updated Category News Views 191

Peeling Back the Scrubs: Hidden Heroes in Vet Medicine Everyone's all-hands-on-deck when it's your furball on the line, but how much do you really know about what happens in those vet offices? Finally, National Veterinary Associates (NVA) is unzipping that mystery with a no-bones-about-it docuseries, Advancing Veterinary Medicine: Our Stories, right out of Austin, Texas....

Continue Reading
Inside Kristallnacht: An XR Journey for a New World

Updated Category News Views 135

Bridging the Past with Powerful Tech: A Journey to Kristallnacht Let's cut to the chase: if there's a time in history that we all need to sear into our collective consciousness, it's Kristallnacht. Forget the mere notion of reading it from a textbook; now you can dive headfirst into the harrowing events of November 9, 1938, thanks to the cutting-edge initiative inside...

Continue Reading

Top 5 Most Recently Viewed Articles

Getinge's Early 2025 Financial Results: Insights and Strategies

Updated Category News Views 521

Sales Growth and Performance Overview Getinge has reported a strong performance for the first quarter of 2025, characterized by an organic sales growth of 6.2%. Despite facing currency headwinds, the medical technology company's positive trajectory continues to impress. The rise in order intake, marked at 2.9%, further cements Getinge's position as a key player in the...

Continue Reading
UnitedHealth's 2025 Outlook: Insights Amid Industry Challenges

Updated Category News Views 1417

UnitedHealth's Anticipated 2025 Outlook Investors eagerly await significant insights into UnitedHealth Group's (NYSE: UNH) projections for 2025 as the company prepares to release its quarterly results. This anticipation follows the recent tragic event involving executive Brian Thompson, whose murder led to the cancellation of crucial investor day presentations. With the...

Continue Reading
Industrial Nitrogen Market Poised for Significant Growth Ahead

Updated Category News Views 126

The Promising Future of the Industrial Nitrogen Market Recent analyses indicate a bright future for the global industrial nitrogen market, which is anticipated to reach a value of USD 38.29 billion in the next few years. This projection reflects a strong compound annual growth rate (CAGR) of 6.1% based on recent evaluations. The growth trend is largely driven by...

Continue Reading
Akeso Showcases Groundbreaking IL-1RAP Antibody Research

Updated Category News Views 206

Akeso Showcases Groundbreaking IL-1RAP Antibody Research Akeso, Inc. (HKEX: 9926.HK) has unveiled promising data from preclinical studies of a new monoclonal antibody known as AK135. This innovative treatment specifically targets the IL-1 receptor accessory protein (IL-1RAP) and effectively blocks multiple pro-inflammatory pathways. The recent findings were presented at a...

Continue Reading
Vor Bio's Pioneering Research in IgA Nephropathy Presentation

Updated Category News Views 164

Vor Bio Unveils Groundbreaking IgA Nephropathy Study at ASN 2025 CAMBRIDGE, Mass. -- Vor Bio, a leader in clinical-stage biotechnology focused on autoimmune diseases, is set to make a significant impact at the upcoming American Society of Nephrology’s Kidney Week 2025. They will present clinical data from a Phase 3 study conducted in collaboration with RemeGen Co., Ltd,...

Continue Reading